Approach to the patient who is intolerant of statin therapy.
暂无分享,去创建一个
[1] L. Iuliano,et al. Do statins cause myopathy by lowering vitamin E levels? , 2010, Medical hypotheses.
[2] A. Kolpakchi,et al. Red yeast rice for dyslipidemia in statin-intolerant patients. , 2010, Annals of internal medicine.
[3] G. Ginsburg,et al. The SLCO1B1*5 genetic variant is associated with statin-induced side effects. , 2009, Journal of the American College of Cardiology.
[4] T. Jacobson. Myopathy with statin–fibrate combination therapy: clinical considerations , 2009, Nature Reviews Endocrinology.
[5] Hans Hoppeler,et al. Association between statin-associated myopathy and skeletal muscle damage , 2009, Canadian Medical Association Journal.
[6] R. Hegele,et al. Narrative Review: Statin-Related Myopathy , 2009, Annals of Internal Medicine.
[7] P. Phillips. Balancing Randomized Trials With Anecdote , 2009, Annals of Internal Medicine.
[8] A. Goldberg,et al. Lowering low-density lipoprotein cholesterol: statins, ezetimibe, bile acid sequestrants, and combinations: comparative efficacy and safety. , 2009, Endocrinology and metabolism clinics of North America.
[9] T. Wolfson,et al. Myotoxic reactions to lipid-lowering therapy are associated with altered oxidation of fatty acids , 2009, Endocrine.
[10] F. Westwood,et al. Blunted Akt/FOXO signalling and activation of genes controlling atrophy and fuel use in statin myopathy , 2009, The Journal of physiology.
[11] A. Stalenhoef,et al. Effects of ubiquinone (coenzyme Q10) on myopathy in statin users , 2008, Current opinion in lipidology.
[12] G. Vladutiu. Genetic predisposition to statin myopathy , 2008, Current Opinion in Rheumatology.
[13] T. Klopstock. Drug-induced myopathies , 2008, Current opinion in neurology.
[14] R. Collins,et al. SLCO1B1 variants and statin-induced myopathy--a genomewide study. , 2008, The New England journal of medicine.
[15] W. Frishman,et al. Statin–Drug Interactions: Not a Class Effect , 2008, Cardiology in review.
[16] P. Thompson,et al. Effectiveness and Tolerability of Every-Other-Day Rosuvastatin Dosing in Patients with Prior Statin Intolerance , 2008, The Annals of pharmacotherapy.
[17] C. Ballantyne,et al. Efficacy and tolerability of fluvastatin XL 80 mg alone, ezetimibe alone, and the combination of fluvastatin XL 80 mg with ezetimibe in patients with a history of muscle-related side effects with other statins. , 2008, The American journal of cardiology.
[18] J. Armitage,et al. The safety of statins in clinical practice , 2007, The Lancet.
[19] Ying Zhang,et al. Determination of pitavastatin in human plasma via HPLC-ESI-MS/MS and subsequent application to a clinical study in healthy Chinese volunteers. , 2007, Clinica chimica acta; international journal of clinical chemistry.
[20] T. A. Jacobson,et al. The broad spectrum of statin myopathy: from myalgia to rhabdomyolysis , 2007, Current opinion in lipidology.
[21] G. Nichols,et al. Does statin therapy initiation increase the risk for myopathy? An observational study of 32,225 diabetic and nondiabetic patients. , 2007, Clinical therapeutics.
[22] C. Gibson,et al. Effects of once weekly rosuvastatin among patients with a prior statin intolerance. , 2007, American Journal of Cardiology.
[23] C. Liu,et al. Efficacy of Monascus purpureus Went rice on lowering lipid ratios in hypercholesterolemic patients , 2007, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.
[24] B. Miskie,et al. Genetic determinants of statin intolerance , 2007, Lipids in Health and Disease.
[25] R. Eckel,et al. Effects of lipoprotein lipase and statins on cholesterol uptake into heart and skeletal muscles⃞ Published, JLR Papers in Press, December 22, 2006. , 2007, Journal of Lipid Research.
[26] Yuichi Sugiyama,et al. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. , 2006, Pharmacology & therapeutics.
[27] D. Figarella-Branger,et al. In vivo and in vitro characterization of skeletal muscle metabolism in patients with statin-induced adverse effects. , 2006, Arthritis and rheumatism.
[28] M. Panas,et al. Presymptomatic neuromuscular disorders disclosed following statin treatment. , 2006, Archives of internal medicine.
[29] C. Glueck,et al. Rosuvastatin 5 and 10 mg/d: a pilot study of the effects in hypercholesterolemic adults unable to tolerate other statins and reach LDL cholesterol goals with nonstatin lipid-lowering therapies. , 2006, Clinical therapeutics.
[30] A. Åsberg,et al. Exposure of atorvastatin is unchanged but lactone and acid metabolites are increased several‐fold in patients with atorvastatin‐induced myopathy , 2006, Clinical pharmacology and therapeutics.
[31] Harlan M Krumholz,et al. Withdrawn: P68 , 2006 .
[32] J. Mckenney,et al. Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. , 2006, The American journal of cardiology.
[33] Alicja R Rudnicka,et al. Statin safety: a systematic review. , 2006, The American journal of cardiology.
[34] John A. Clark,et al. Statin safety: an appraisal from the adverse event reporting system. , 2006, American Journal of Cardiology.
[35] J. Stein,et al. Outcomes in 45 patients with statin-associated myopathy. , 2005, Archives of internal medicine.
[36] E. Bruckert,et al. Mild to Moderate Muscular Symptoms with High-Dosage Statin Therapy in Hyperlipidemic Patients —The PRIMO Study , 2005, Cardiovascular Drugs and Therapy.
[37] N. Bresolin,et al. Muscle coenzyme Q10 level in statin-related myopathy. , 2005, Archives of neurology.
[38] B. Cheung,et al. Pharmacokinetics of pitavastatin in subjects with Child-Pugh A and B cirrhosis. , 2005, British journal of clinical pharmacology.
[39] Michael Schachter,et al. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update , 2005, Fundamental & clinical pharmacology.
[40] Richard Platt,et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. , 2004, JAMA.
[41] R. Naviaux,et al. Statin myotoxicity is associated with changes in the cardiopulmonary function. , 2004, Atherosclerosis.
[42] P. Giral,et al. A Comprehensive Description of Muscle Symptoms Associated with Lipid-Lowering Drugs , 2003, Cardiovascular Drugs and Therapy.
[43] E. Toma,et al. Statin-associated myopathy with normal creatine kinase levels. , 2003, Annals of internal medicine.
[44] P. Thompson,et al. Statin-associated myopathy. , 2003, JAMA.
[45] Roger B. Davis,et al. Screening for statin-related toxicity: the yield of transaminase and creatine kinase measurements in a primary care setting. , 2003, Archives of internal medicine.
[46] C. M. White. A Review of the Pharmacologic and Pharmacokinetic Aspects of Rosuvastatin , 2002, Journal of clinical pharmacology.
[47] R. Wolfram,et al. Muscular Side Effects of Statins , 2002, Journal of cardiovascular pharmacology.
[48] P. Mckelvie,et al. Myopathy Associated With HMG-CoA Reductase Inhibitors (Statins): A Series of 10 Patients and Review of the Literature , 2002, Journal of clinical neuromuscular disease.
[49] B. Ma,et al. Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization. , 2002, Drug metabolism and disposition: the biological fate of chemicals.
[50] Jennie Chang,et al. Cerivastatin and reports of fatal rhabdomyolysis. , 2002, The New England journal of medicine.
[51] I. Vermes,et al. Association of polymorphism in the cytochrome CYP2D6 and the efficacy and tolerability of simvastatin , 2001, Clinical pharmacology and therapeutics.
[52] M. Barbagallo,et al. Effects of simvastatin and atorvastatin administration on insulin resistance and respiratory quotient in aged dyslipidemic non-insulin dependent diabetic patients. , 2000, Atherosclerosis.
[53] F. Bernini,et al. New insights into the pharmacodynamic and pharmacokinetic properties of statins. , 1999, Pharmacology & therapeutics.
[54] R. Elashoff,et al. Cholesterol-lowering effects of a proprietary Chinese red-yeast-rice dietary supplement. , 1999, The American journal of clinical nutrition.
[55] H. Hartung,et al. Pravastatin-associated inflammatory myopathy. , 1992, The New England journal of medicine.
[56] P. Thompson,et al. How do you treat patients with myalgia who take statins? , 2009, Current atherosclerosis reports.
[57] N. Goldenberg,et al. Low serum 25 (OH) vitamin D levels (<32 ng/mL) are associated with reversible myositis-myalgia in statin-treated patients. , 2009, Translational research : the journal of laboratory and clinical medicine.
[58] E. Carlini,et al. Comparative Effects of Fibrates on Drug Metabolizing Enzymes in Human Hepatocytes , 2004, Pharmaceutical Research.
[59] S. Grundy,et al. ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins. , 2002, Stroke.
[60] J. Mckenney,et al. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). , 2001, JAMA.
[61] R. Kim,et al. Molecular basis of ethnic differences in drug disposition and response. , 2001, Annual review of pharmacology and toxicology.